P901: DARATUMUMAB, IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PRE-TREATED WITH A LENALIDOMIDE-BASED REGIMEN: FINAL OUTCOMES OF THE PHASE 2 DARIA STUDY

類似資料

• Increased serum B‐cell maturation antigen levels evaluated with an Elecsys‐based serum B‐cell maturation antigen assay have a negative prognostic value in patients with newly diagnosed multiple myeloma
  著者:: Evangelos Terpos, 等
  出版事項: (2025-02-01)
• P861: PERSISTENT BONE MARROW AND IMAGING MRD NEGATIVITY AS CRITERIA TO STOP LENALIDOMIDE MAINTENANCE FOLLOWING ASCT: PRELIMINARY RESULTS OF A SINGLE-CENTER PROSPECTIVE COHORT STUDY
  著者:: Panagiotis Malandrakis, 等
  出版事項: (2023-08-01)
• Prevalence of MGCS Among Patients With Monoclonal Gammopathies
  著者:: Foteini Theodorakakou, 等
  出版事項: (2023-06-01)
• PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA
  著者:: Ioannis Ntanasis-Stathopoulos, 等
  出版事項: (2023-08-01)
• Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study
  著者:: Vassiliki Spiliopoulou, 等
  出版事項: (2023-03-01)